Regorafenib as second-line therapy in hepatocellular carcinoma

被引：25
|
作者：
Duffy, Austin G. [1 ]
Greten, Tim F. [1 ]
机构：
[1] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2017年 / 14卷 / 03期
关键词：
SORAFENIB;
D O I：
10.1038/nrgastro.2017.7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive result in a phase III study evaluating regorafenib challenges us to weigh its clinical significance as well as its real-world benefits and potential harms.
引用
收藏
页码：141 / 142
页数：2
相关论文
共 50 条
12345